Therapeutic kinase inhibitors
Author(s)
Bibliographic Information
Therapeutic kinase inhibitors
(Current topics in microbiology and immunology, v. 355)
Springer, c2012
Available at 7 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Description and Table of Contents
Description
Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as "chemotherapy" and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates.
This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors and authors hope these lessons will be instructive for the novice as well as the expert.
Table of Contents
Preface.- Fundamentals.- Setting up a Kinase Discovery and Development Project.-Drug Efficacy Testing in Mice.- Kinase Targets and Disease.- Gastrointestinal Stromal Tumors (GISTS).-EGFR-Mutant Lung Cancer.- Targeting Oncogenic BRAF in Human Cancer.- Beyond BRAF in Melanoma.- JAK-mutant Myeloproliferative Neoplasms.- Will Kinase Inhibitors Make It as Glioblastoma Drugs?.- Perspectives.- Predictive Genomic Biomarkers.- Epigenetic Biomarkers.- Adjuvant Trials of Targeted Agents: The Newest Battleground in the War on Cancer.- Subject Index
by "Nielsen BookData"